NeuroPace, Inc. (NASDAQ:NPCE) Insider Martha Morrell Sells 78,334 Shares

NeuroPace, Inc. (NASDAQ:NPCE) insider Martha Morrell sold 78,334 shares of NeuroPace stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $13.72, for a total value of $1,074,742.48. Following the completion of the sale, the insider now owns 81,993 shares in the company, valued at approximately $1,124,943.96. This trade represents a 48.86 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Martha Morrell also recently made the following trade(s):

• On Wednesday, January 29th, Martha Morrell sold 100 shares of NeuroPace stock. The shares were sold at an average price of $15.00, for a total value of $1,500.00.
• On Friday, January 24th, Martha Morrell sold 3,200 shares of NeuroPace stock. The stock was sold at an average price of $15.01, for a total value of $48,032.00.

NeuroPace Trading Up 2.4 %

Shares of NeuroPace stock traded up $0.32 during mid-day trading on Tuesday, hitting $13.84. 213,262 shares of the stock were exchanged, compared to its average volume of 240,635. The company has a 50-day simple moving average of $12.53 and a 200 day simple moving average of $9.50. The company has a current ratio of 5.59, a quick ratio of 4.77 and a debt-to-equity ratio of 6.03. The stock has a market capitalization of $413.12 million, a price-to-earnings ratio of -13.84 and a beta of 2.05. NeuroPace, Inc. has a twelve month low of $5.45 and a twelve month high of $17.37.

Institutional Trading of NeuroPace

Hedge funds have recently bought and sold shares of the company. Wells Fargo & Company MN raised its holdings in NeuroPace by 54.2% in the 4th quarter. Wells Fargo & Company MN now owns 6,483 shares of the company’s stock valued at $73,000 after acquiring an additional 2,279 shares during the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of NeuroPace in the fourth quarter valued at $29,000. Financial Advocates Investment Management increased its stake in NeuroPace by 20.0% in the third quarter. Financial Advocates Investment Management now owns 18,000 shares of the company’s stock valued at $125,000 after purchasing an additional 3,000 shares during the last quarter. Bank of New York Mellon Corp lifted its position in NeuroPace by 21.2% during the fourth quarter. Bank of New York Mellon Corp now owns 29,342 shares of the company’s stock worth $328,000 after buying an additional 5,133 shares during the period. Finally, Geode Capital Management LLC lifted its position in NeuroPace by 1.8% during the fourth quarter. Geode Capital Management LLC now owns 322,973 shares of the company’s stock worth $3,615,000 after buying an additional 5,781 shares during the period. Institutional investors and hedge funds own 78.83% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on NPCE shares. Wells Fargo & Company boosted their target price on NeuroPace from $13.00 to $17.00 and gave the stock an “overweight” rating in a research report on Thursday, January 30th. UBS Group started coverage on NeuroPace in a research report on Tuesday, January 21st. They set a “buy” rating and a $17.00 target price on the stock. Finally, JPMorgan Chase & Co. increased their target price on NeuroPace from $9.00 to $14.00 and gave the company an “overweight” rating in a report on Tuesday, December 17th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, NeuroPace currently has an average rating of “Moderate Buy” and an average target price of $14.80.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.